医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1593 医美概念股

已收盘 03-18 16:00:00

1,125.193

+26.144

+2.38%

最高1,131.670	最低1,098.147	成交量5,244万
今开1,102.076	昨收1,099.049	日振幅3.05%
总市值0.00	流通市值0.00	总股本0.00
成交额7.55亿	换手率--	流通股本0.00
市净率1.596444	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"医美概念股","latestPrice":1125.1934,"timestamp":1773821283690,"preClose":1099.0492,"halted":0,"volume":52441634,"delay":0,"changeRate":0.023788,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":26.144165,"latestTime":"03-18 16:00:00","open":1102.0757,"high":1131.6702,"low":1098.1469,"amount":755323376,"amplitude":0.030502,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773883800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1773797400000,1773806400000],[1773810000000,1773820800000]],"pbRate":1.596444,"peRate":23.369116,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1593","defaultTab":"news","newsList":[{"id":"2620408781","title":"今年以来瑞丽口岸出入境客流超100万人次","url":"https://stock-news.laohu8.com/highlight/detail?id=2620408781","media":"云南日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620408781?lang=zh_cn&edition=full","pubTime":"2026-03-18 03:46","pubTimestamp":1773776760,"startTime":"0","endTime":"0","summary":"转自：云南日报记者近日从瑞丽出入境边防检查站获悉，今年以来，截至3月13日，瑞丽口岸出入境客流超过100万人次，同比增长8.7%，日均通关流量超1.4万人次。外国人入境卡网上填报、货运车辆信用通关安全管理系统等出入境便利化措施的落地实施，进一步激活了口岸跨境往来热度，形成“探亲访友+跨境旅游+商务往来”的多元格局，不仅带动边民互市贸易繁荣，推动跨境贸易蓬勃发展，更让瑞丽口岸成为深化中缅友好互通的重要引擎。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-03-18/doc-inhrivey5031206.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1209","02135","BK1593"],"gpt_icon":0},{"id":"2620286154","title":"三生制药(01530.HK)拟3月30日举行董事会会议审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2620286154","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620286154?lang=zh_cn&edition=full","pubTime":"2026-03-17 17:37","pubTimestamp":1773740224,"startTime":"0","endTime":"0","summary":"格隆汇3月17日丨三生制药(01530.HK)宣布，公司将于2026年3月30日(星期一)举行董事会会议，藉以(其中包括)审议及批准公司及其附属公司截至2025年12月31日止年度之年度业绩及其发布，并考虑派发截至2025年12月31日止年度之末期股息(如有)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260317/32075140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1593","BK1161","HK0000165453.HKD","BK1583","01530"],"gpt_icon":0},{"id":"2620449806","title":"招银国际：料中国医疗行业基本面加速向好 推荐买信达生物(01801)三生制药(01530)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2620449806","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620449806?lang=zh_cn&edition=full","pubTime":"2026-03-17 15:07","pubTimestamp":1773731228,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，MSCI中国医疗指数2026年初至今累计上涨0.6%，跑赢MSCI中国指数3.5%。医药行业近期明显回调，特别是创新药板块回调幅度较大。同时，AI制药技术突破与中国创新药踏出海外BD的爆发形成双重共振，该行预计行业基本面加速向好。该行表示，推荐买入信达生物、三生制药、加科思、固生堂 、药明合联，目标价分别110.62港元、37.43港元、10.34港元、44.95港元及88港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1219","LU2097828474.EUR","BK1574","LU1969619763.USD","BK1141","LU0455707207.USD","BK1589","LU2097828714.EUR","BK1161","SG9999014674.SGD","BK1593","LU2097828557.USD","02273","02268","LU2097828805.USD","LU2328871848.SGD","LU2488822045.USD","01530","01801","BK1583","159891","LU0502904849.HKD","LU2242644610.SGD","LU2097828631.EUR","HK0000165453.HKD","01167"],"gpt_icon":0},{"id":"2620641495","title":"港股创新药概念震荡走高 三生制药涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620641495","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620641495?lang=zh_cn&edition=full","pubTime":"2026-03-17 10:51","pubTimestamp":1773715883,"startTime":"0","endTime":"0","summary":"港股创新药概念震荡走高 三生制药涨超7%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603173674281470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["VXUS","BK1574","01530","HK0000165453.HKD","06978","159992","BK1161","BK1593","BK1583","BK4588","BK4585"],"gpt_icon":0},{"id":"2619165464","title":"康哲药业(00867)公布2025年业绩 拥有人应占溢利约14.89亿元 同比减少8.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619165464","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619165464?lang=zh_cn&edition=full","pubTime":"2026-03-16 22:52","pubTimestamp":1773672729,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 公布2025年业绩，营业额同比增长 9.95%至82.12亿元;公司拥有人应占溢利约14.89亿元，同比减少8.08%;每股基本盈利0.6154元，拟派末期股息每股0.1366 元。已上市创新药加速放量，逐步形成推广规模效应。回望2025年，康哲药业已实现里程碑式的战略突破。集团正以卓越的发展韧性与战略张力，稳步成长为一家根植中国、竞逐全球新兴市场的创新驱动型国际化医药企业，为全球医药健康事业创造长远价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BMCWC346.EUR","SG9999004220.SGD","SG9999015978.USD","SG9999015986.USD","BK1593","LU2488822045.USD","SG9999015945.SGD","IE00BVYPNQ40.USD","SG9999015952.SGD","IE00BVYPNP33.GBP","IE00BYV24P56.USD","BK1191","00867","IE00BGHQDM52.EUR"],"gpt_icon":0},{"id":"2619464348","title":"复星医药（600196）披露控股子公司药品获临床试验批准的公告，3月16日股价上涨0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619464348","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619464348?lang=zh_cn&edition=full","pubTime":"2026-03-16 22:40","pubTimestamp":1773672030,"startTime":"0","endTime":"0","summary":"截至2026年3月16日收盘，复星医药报收于25.61元，较前一交易日上涨0.23%，最新总市值为683.9亿元。近日，上海复星医药（集团）股份有限公司控股子公司复宏汉霖收到国家药监局批准，同意HLX07联合斯鲁利单抗注射液和化疗用于晚期鳞状非小细胞肺癌治疗开展临床试验。复宏汉霖拟于条件具备后在中国境内开展相关临床研究。截至2026年3月16日，全球范围内尚无同类联合用药治疗方案获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600037042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0096","BK1593","BK0183","BK0060","BK1515","600196","BK1191","BK0188","02196","BK0012","BK0028","BK0187","BK0175","BK0239"],"gpt_icon":0},{"id":"2619645427","title":"复星医药(600196.SH)：HLX07联合斯鲁利单抗注射液和化疗用于晚期鳞状非小细胞肺癌(sqNSCLC)治疗获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2619645427","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619645427?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:44","pubTimestamp":1773657849,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司收到国家药品监督管理局关于同意HLX07联合斯鲁利单抗注射液和化疗用于晚期鳞状非小细胞肺癌治疗开展临床试验的批准。复宏汉霖拟于条件具备后在中国境内开展该治疗方案的相关临床研究。截至本公告日期，于全球范围尚无同类联合用药治疗方案获批上市。截至2025年2月，集团现阶段针对该治疗方案的累计研发投入约为人民币0.93亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414398.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0175","BK0187","BK0096","BK1515","BK0183","BK0060","BK1593","BK0239","02196","BK0188","BK0196","600196","BK0028","BK1191"],"gpt_icon":0},{"id":"2619454682","title":"昊海生物科技(06826)：眼内用交联透明质酸钠凝胶产品获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2619454682","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619454682?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:36","pubTimestamp":1773657416,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，上海昊海生物科技股份有限公司(以下简称“公司”)全资子公司上海其胜生物制剂有限公司(以下简称“其胜生物”)于近日收到国家药品监督管理局颁发的关于眼内用交联透明质酸钠凝胶产品(以下简称“本产品”)的《中华人民共和国医疗器械注册证》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09997","BK1161","BK1583","159883","09996","BK1593","BK1574","BK1222","BK1100","06826"],"gpt_icon":0},{"id":"2619345450","title":"现代牙科(03600)发盈喜，预期2025年度纯利约5.9亿港元至6.1亿港元 同比增加约45.0%至49.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619345450","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619345450?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:35","pubTimestamp":1773657335,"startTime":"0","endTime":"0","summary":"智通财经APP讯，现代牙科 发布公告，集团预期：截至2025年12月31日止年度的收益将介乎36.75亿港元至37.75亿港元，较截至2024年12月31日止年度的收益约33.64亿港元，增加约9.2%至12.2%;2025年财政年度的未计利息、税项、折旧及摊销前盈利将介乎9.2亿港元至9.5亿港元，较2024年财政年度的EBITDA约7.088亿港元，增加约29.8%至34.0%;及2025年财政年度的纯利将介乎5.9亿港元至6.1亿港元，较2024年财政年度的纯利约4.069亿港元，增加约45.0%至49.9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"现代牙科(03600)发盈喜，预期2025年度纯利约5.9亿港元至6.1亿港元 同比增加约45.0%至49.9%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03600","BK1583","BK1593","BK1100"],"gpt_icon":0},{"id":"2619045967","title":"复星医药最新公告：控股子公司用于治疗雄激素脱发的药品LBP-ShC4获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619045967","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619045967?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:50","pubTimestamp":1773654632,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，控股子公司上海菌济健康科技有限公司收到国家药品监督管理局关于同意LBP-ShC4开展临床试验的批准。LBP-ShC4是复星医药自主研发的活体生物治疗产品，拟用于治疗雄激素脱发（AGA）。截至2026年2月，针对LBP-ShC4的累计研发投入约为0.20亿元。截至本公告日期，于全球范围尚无用于治疗雄激素脱发（AGA）的活体生物治疗产品（包括单药或联合治疗方案）获批上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600025145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0096","BK0196","BK0175","BK0060","BK0028","BK0012","BK0188","BK1191","02196","BK1515","BK1593","BK0183","BK0187","600196"],"gpt_icon":0},{"id":"2619043353","title":"四川“学霸”卖牙套，闯关IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2619043353","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619043353?lang=zh_cn&edition=full","pubTime":"2026-03-16 11:23","pubTimestamp":1773631416,"startTime":"0","endTime":"0","summary":"近日，据证监会披露，正雅齿科已在浙江证监局完成IPO辅导备案，其IPO辅导券商由中金公司、国海证券组合变更为中信建投。四川“学霸”卖牙套根据公开报道，正雅齿科的创始人为姚峻峰，1975年生于四川成都，大学学的是软件与信息工程，后来在英国赫尔大学获得MBA学位。三年后，公司完成首例Smartee临床病例测试。另外，种植牙价格因集采价格骤降，隐形矫治器价格战导致客单价腰斩，依赖高溢价的口腔机构正在失去利润支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1773535428076534904","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1593","BK1583","06699","BK1100","BK1587"],"gpt_icon":0},{"id":"2619127710","title":"每周股票复盘：复星医药（600196）三款新药获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619127710","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619127710?lang=zh_cn&edition=full","pubTime":"2026-03-15 01:40","pubTimestamp":1773510018,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，复星医药报收于25.55元，较上周的25.91元下跌1.39%。本周，复星医药3月10日盘中最高价报26.23元。本周关注点公司公告汇总：复星医药三款自研新药获临床试验批准。复星医药控股子公司上海复星医药产业发展有限公司收到国家药品监督管理局批准，同意其自主研发的口服小分子创新药FXS0683片用于血液系统恶性肿瘤开展临床试验。复星医药产业拟于条件具备后在中国境内开展I期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02196","BK0183","BK1191","BK1593","BK0012","BK0196","BK0175","BK0187","BK0096","BK0028","BK0060","600196","BK0239","BK0188","BK1515"],"gpt_icon":0},{"id":"2619128679","title":"今年以来中缅边境瑞丽口岸出入境客流量破百万人次","url":"https://stock-news.laohu8.com/highlight/detail?id=2619128679","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619128679?lang=zh_cn&edition=full","pubTime":"2026-03-14 14:46","pubTimestamp":1773470760,"startTime":"0","endTime":"0","summary":"今年以来中缅边境瑞丽口岸出入境客流量破百万人次中新社云南德宏3月14日电 瑞丽出入境边防检查站14日发布消息称，截至3月13日15时，中缅边境瑞丽口岸今年以来出入境客流量突破100万人次，同比增长8.7%。瑞丽口岸位于云南省德宏傣族景颇族自治州瑞丽市，是中缅边境最大陆路口岸。截至目前，该口岸日均通关流量超1.4万人次，呈现出入境客流持续攀升的繁忙景象。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-03-14/doc-inhqxwhp3334105.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-03-14/doc-inhqxwhp3334105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1593","02135","BK1209"],"gpt_icon":0},{"id":"1105156245","title":"康哲药业肾病贫血新药德司达他片获中国药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1105156245","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105156245?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:45","pubTimestamp":1773398712,"startTime":"0","endTime":"0","summary":"康哲药业宣布，其用于治疗肾病贫血的创新药物德司达他片已正式获得中国国家药品监督管理局的上市批准。这一重要进展标志着公司在肾脏疾病治疗领域取得了新的突破。\n德司达他片作为一种新型口服药物，其获批将为国内肾病贫血患者提供更便捷、有效的治疗选择。此次获批也进一步丰富了康哲药业在慢性肾病治疗领域的产品管线，有望为公司带来新的业绩增长点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015986.USD","BK1593","00867","IE00BVYPNP33.GBP","IE00BMCWC346.EUR","BK1191","IE00BGHQDM52.EUR","IE00BVYPNQ40.USD","SG9999015978.USD","IE00BYV24P56.USD","SG9999015952.SGD","SG9999015945.SGD","LU2488822045.USD","SG9999004220.SGD"],"gpt_icon":0},{"id":"2619119691","title":"康哲药业(00867)：肾性贫血新药德昔度司他片中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2619119691","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619119691?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:44","pubTimestamp":1773398665,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 公布，肾性贫血新药德昔度司他片上市许可申请已于2026年3月13日获得中国国家药品监督管理局批准。CKD患者肾功能逐渐丧失，最终出现肾衰竭。如果肾功能受损，肾脏生成EPO水平下降或完全不生成EPO，从而导致贫血。产品中国III期临床试验取得了积极结果。扩展期研究结果显示，产品可使Hb水平长期维持在达标水平，且安全性良好。此外，产品还可以显著降低铁调素水平，纠正铁代谢紊乱。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康哲药业(00867)：肾性贫血新药德昔度司他片中国获批上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BVYPNQ40.USD","IE00BVYPNP33.GBP","SG9999015986.USD","SG9999004220.SGD","SG9999015952.SGD","IE00BGHQDM52.EUR","SG9999015978.USD","BK1191","IE00BMCWC346.EUR","00867","BK1593","SG9999015945.SGD","LU2488822045.USD","IE00BYV24P56.USD"],"gpt_icon":0},{"id":"2619719840","title":"复星医药(600196.SH)控股子公司FXS0683片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619719840","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619719840?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:30","pubTimestamp":1773394256,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)发布公告，近日，公司控股子公司上海复星医药产业发展有限公司(简称“复星医药产业”)收到国家药品监督管理局关于同意FXS0683片(简称“FXS0683”)用于血液系统恶性肿瘤开展临床试验的批准。复星医药产业拟于条件具备后于中国境内开展FXS0683的I期临床研究。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/astock/13.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/13.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413656.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0175","BK0028","BK0183","600196","BK1515","BK0188","BK0239","BK0012","BK0096","BK1593","BK1191","BK0196","BK0060","BK0187","02196"],"gpt_icon":0},{"id":"2619167016","title":"丽丰控股(01125)发盈警，预期中期股东应占综合亏损同比增加不少于100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619167016","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619167016?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:02","pubTimestamp":1773392554,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽丰控股(01125)发布公告，预期截至2026年1月31日止6个月(该期间)的本公司拥有人应占未经审核综合亏损将较截至2025年1月31日止6个月的亏损约1.64亿港元增加不少于100%。亏损增加的主要原因为该期间因出售横琴创新方第二期的一幢住房大楼及撇减横琴创新方第二期的物业而产生亏损。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413630.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"丽丰控股(01125)发盈警，预期中期股东应占综合亏损同比增加不少于100%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1240","BK1593","01125"],"gpt_icon":0},{"id":"2619160101","title":"每日卖空追踪 | 时代天使 03月13日卖空量成交3.38万股，卖空比例为17.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619160101","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619160101?lang=zh_cn&edition=full","pubTime":"2026-03-13 16:30","pubTimestamp":1773390637,"startTime":"0","endTime":"0","summary":"时代天使北京时间03月13日，跌1.06%，卖空量成交3.38万股，较上一交易日增加39.67%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313163608a6bd1e17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313163608a6bd1e17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1587","BK1593","06699","BK1100"],"gpt_icon":0},{"id":"2619115474","title":"【券商聚焦】华泰证券：部分国际美妆龙头大陆区持续回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2619115474","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619115474?lang=zh_cn&edition=full","pubTime":"2026-03-13 09:03","pubTimestamp":1773363782,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券表示，海外美妆/奢侈品/消费龙头25年全年及25Q4业绩陆续披露。欧莱雅管理层表示，随着中国股市行情向好，中国消费者对奢侈品牌及医学美妆领域的高端产品购买意愿有所恢复；管理层亦称今年年初以来中国消费者对高端产品的购买信心回暖，且这一趋势没有改变，中国大陆整体势头向好。该机构认为中国大陆高端消费回暖态势有望继续。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976416","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2148510915.USD","LU1781817850.SGD","LU1934453819.USD","LU1328615791.USD","LU0164865239.USD","BK0188","BK1593","LU1064130708.USD","LU1064131003.USD","02145","LU2242644610.SGD","BK0276","LU1580142542.USD","SG9999004311.SGD","BK0012","BK1215","601688","LU1808992512.USD","LU0871576103.HKD","02367","BK0183","01830","BK1207","LU0531971595.HKD","BK0028","LU0455707207.USD","LU0502904849.HKD","LU1979443071.USD","LU0039217434.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2619503311","title":"复锐医疗科技将于2026年3月23日公布2025年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2619503311","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619503311?lang=zh_cn&edition=full","pubTime":"2026-03-12 17:52","pubTimestamp":1773309120,"startTime":"0","endTime":"0","summary":"业绩电话会将于2026年3月24日举行 香港2026年3月12日 /美通社/ -- 复锐医疗科技有限公司，一家全球化的美丽健康集团，致力于以能量源设备及注射填充产品为核心构建客户导向的美丽健康生态系统，今日宣布其将于2026年3月23日（星期一）公布截至2025年12月31日止年度的经审核综合全年业绩。复锐医疗科技为中国领先的医疗健康产业集团复星医药的控股子公司，自 2017年9月起在香港联合交易所主板上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4908643_ZH08643_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1100","BK1593","01696","BK1585"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0263},{"period":"3month","weight":0.0157},{"period":"6month","weight":-0.0255},{"period":"1year","weight":0.0714},{"period":"ytd","weight":0.0093}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1593","nameEN":"BK1593"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医美概念股,BK1593,医美概念股股票,医美概念股股票老虎,医美概念股股票老虎国际,医美概念股行情,医美概念股股票行情,医美概念股股价,医美概念股股市,医美概念股股票价格,医美概念股股票交易,医美概念股股票购买,医美概念股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}